HomeCompareGEOVF vs PFE

GEOVF vs PFE: Dividend Comparison 2026

GEOVF yields 27.24% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GEOVF wins by $63.1K in total portfolio value
10 years
GEOVF
GEOVF
● Live price
27.24%
Share price
$7.34
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$112.7K
Annual income
$13,705.74
Full GEOVF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — GEOVF vs PFE

📍 GEOVF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGEOVFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GEOVF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GEOVF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GEOVF
Annual income on $10K today (after 15% tax)
$2,315.00/yr
After 10yr DRIP, annual income (after tax)
$11,649.88/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PFE beats the other by $10,670.02/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GEOVF + PFE for your $10,000?

GEOVF: 50%PFE: 50%
100% PFE50/50100% GEOVF
Portfolio after 10yr
$81.1K
Annual income
$19,982.23/yr
Blended yield
24.63%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

GEOVF
Analyst Ratings
1
Buy
Consensus: Buy
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GEOVF buys
0
PFE buys
0
No recent congressional trades found for GEOVF or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGEOVFPFE
Forward yield27.24%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$112.7K$49.6K
Annual income after 10y$13,705.74$26,258.71
Total dividends collected$74.0K$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyHold

Year-by-year: GEOVF vs PFE ($10,000, DRIP)

YearGEOVF PortfolioGEOVF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$13,424$2,723.53$9,153$693.39+$4.3KGEOVF
2$17,780$3,416.77$8,593$849.25+$9.2KGEOVF
3$23,254$4,229.57$8,336$1,066.78+$14.9KGEOVF
4$30,052$5,169.89$8,437$1,384.80+$21.6KGEOVF
5$38,399$6,244.07$9,013$1,875.40+$29.4KGEOVF
6$48,544$7,456.58$10,306$2,680.72+$38.2KGEOVF
7$60,752$8,809.80$12,820$4,101.38+$47.9KGEOVF
8$75,309$10,304.01$17,673$6,826.70+$57.6KGEOVF
9$92,517$11,937.32$27,543$12,591.86+$65.0KGEOVF
10$112,699$13,705.74$49,560$26,258.71+$63.1KGEOVF

GEOVF vs PFE: Complete Analysis 2026

GEOVFStock

Genovis AB (publ.) designs, develops, and sells tools for development of drugs for customers in the pharmaceutical and medical device industries. The company offers FabALACTICA, a cysteine protease that digests human IgG1; FabRICATOR, an enzyme that primarily digests the hinge region of IgG; and FabRICATOR Z, an enzyme for the digestion of mouse IgG2a and IgG3, as well as for generating a homogenous pool of F(ab')2 and Fc fragments. It also provides FabULOUS (SpeB), an enzyme for the digestion of IgG in the hinge region; and GingisKHAN, a cysteine protease that digests human IgG1 at a specific site above the hinge. In addition, the company offers GingisREX, a cysteine protease that specifically digests peptide bonds C-terminally to arginine residues; and IgGZERO (EndoS), an endoglycosidase from Streptococcus pyogenes that specifically hydrolyzes N-linked glycans in the Fc-region of native IgG. Further, it provides IgGZERO LE, an endoglycosidase acting on complex type N-glycans from Streptococcus pyogenes; deGlycIT, an IgGZERO (EndoS) enzyme for agarose beads for deglycosylation of Fc-glycans; GlycINATOR an endoglycosidase from Streptococcus pyogenes that hydrolyzes the all glycoforms structure; and GlycINATOR (EndoS2), an endoglycosidase from Streptococcus pyogenes that specifically hydrolyzes glycans at the Fc glycosylation site of IgG. Additionally, the company offers GlyCLICK, a site-specific conjugation technology used for IgG on enzymatic remodeling of the Fc glycans and click chemistry; SialEXO, a sialidase product for the removal and analysis of sialic acids; enzymes for O-glycans; and antibody fragmentation services, as well as operates online store for its products. It serves pharmaceutical and biotech, contract research, and contract manufacturing companies in Sweden, Europe, North America, and Asia. The company has a collaboration with Waters Corporation. Genovis AB (publ.) was founded in 1999 and is based in Lund, Sweden.

Full GEOVF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this GEOVF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GEOVF vs SCHDGEOVF vs JEPIGEOVF vs OGEOVF vs KOGEOVF vs MAINGEOVF vs JNJGEOVF vs MRKGEOVF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.